chunk_id stringlengths 23 27 | chunk stringlengths 40 4.57k | source_url stringclasses 246
values | title stringclasses 246
values | chunk_idx int64 0 68 | chunk_start_char int64 0 20.9k | chunk_end_char int64 49 21k |
|---|---|---|---|---|---|---|
0001368148-22-000060#s788 | The costs that the Company expects to incur in connection with the Plan are subject to a number of assumptions, and actual results may differ from the Company’s original estimate. | 0001368148-22-000060 | Athersys 8-K 2022-06-02 | 4 | 788 | 243 |
0001368148-22-000060#s968 | The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the Plan. | 0001368148-22-000060 | Athersys 8-K 2022-06-02 | 5 | 968 | 218 |
0001368148-22-000060#s1123 | If the Company subsequently determines that it will incur additional significant costs associated with the Plan, it will amend this Current Report on Form 8-K to disclose such information. | 0001368148-22-000060 | Athersys 8-K 2022-06-02 | 6 | 1,123 | 252 |
0001368148-22-000060#s1472 | On May 31, 2022, the Company notified Mr. William (BJ) Lehmann, the Company’s President, Chief Operating Officer and Secretary, of the cessation of his employment as part of the Plan, effective immediately. | 0001368148-22-000060 | Athersys 8-K 2022-06-02 | 7 | 1,472 | 1,678 |
0001368148-22-000060#s1679 | Under the terms of Mr. Lehmann’s Employment Agreement, dated as of December 3, 2021, his separation constitutes a termination by the Company other than for “cause.” Also, on May 31, 2022, the Company notified Dr. John Harrington, the Company’s Executive Vice President and Chief Scientific Officer, of the cessation of h... | 0001368148-22-000060 | Athersys 8-K 2022-06-02 | 8 | 1,679 | 1,851 |
0001368148-22-000060#s2059 | Under the terms of Dr. Harrington’s Employment Agreement, dated as of December 3, 2021, his separation constitutes a termination by the Company other than for “cause.” On June 1, 2022, the Company notified Mr. Ivor Macleod, the Company’s Chief Financial Officer, of the cessation of his employment as part of the Plan, e... | 0001368148-22-000060 | Athersys 8-K 2022-06-02 | 9 | 2,059 | 1,815 |
0001368148-22-000060#s2403 | Under the terms of Mr. Macleod’s Employment Agreement, dated as of December 3, 2021, his separation constitutes a termination by the Company other than for “cause.” | 0001368148-22-000060 | Athersys 8-K 2022-06-02 | 10 | 2,403 | 1,636 |
0001368148-22-000060#s2595 | On May 20, 2022, the Company issued a press release related to the results of the TREASURE study, the clinical trial of its partner in Japan, HEALIOS K.K., evaluating the safety and efficacy of administration of the Company’s MultiStem cell therapy for the treatment of ischemic stroke. | 0001368148-22-000060 | Athersys 8-K 2022-06-02 | 11 | 2,595 | 2,881 |
0001368148-22-000060#s2882 | The full text of the Company’s press release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | 0001368148-22-000060 | Athersys 8-K 2022-06-02 | 12 | 2,882 | 3,036 |
0001368148-22-000060#s3114 | Description 99.1 Press release issued by Athersys, Inc. on May 20, 2022. | 0001368148-22-000060 | Athersys 8-K 2022-06-02 | 13 | 3,114 | 3,186 |
0001368148-22-000060#s3187 | 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) | 0001368148-22-000060 | Athersys 8-K 2022-06-02 | 14 | 3,187 | 3,266 |
0001213900-25-026300#s63 | On March 30, 2025, the Board of Directors (the “Board”) of Agrify Corporation (the “Company”) approved the discontinuation (the “Discontinuation”) of the Company’s legacy extraction business, which includes hydrocarbon, alcohol, solventless, post-processing, and lab equipment (the “Extraction Business”), in order to re... | 0001213900-25-026300 | Agrify 8-K 2025-03-31 | 0 | 63 | 439 |
0001213900-25-026300#s452 | In connection with the Discontinuation, the Company expects to reduce its workforce by nine employees by April 1, 2025 and to dispose of any remaining inventory relating to the Extraction Business. | 0001213900-25-026300 | Agrify 8-K 2025-03-31 | 1 | 452 | 248 |
0001213900-25-026300#s650 | As of the filing of this Current Report on Form 8-K, the Company is in the process of quantifying the charges it will incur under generally accepted accounting principles as a result of the Discontinuation. | 0001213900-25-026300 | Agrify 8-K 2025-03-31 | 2 | 650 | 856 |
0001213900-25-026300#s857 | To the extent that the Company determines that material charges will be incurred in connection with the Discontinuation, the Company will file an amendment to this Current Report on Form 8-K within four business days after the determination is made, which amendment will disclose the estimated amount of the charges. | 0001213900-25-026300 | Agrify 8-K 2025-03-31 | 3 | 857 | 966 |
0001213900-25-026300#s1219 | Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning the Company and other matters. | 0001213900-25-026300 | Agrify 8-K 2025-03-31 | 4 | 1,219 | 1,414 |
0001213900-25-026300#s1415 | All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements including, without limitation, statements regarding the timing and magnitude of the expected workforce reduction and its intention to refocus resources on its hemp... | 0001213900-25-026300 | Agrify 8-K 2025-03-31 | 5 | 1,415 | 1,566 |
0001213900-25-026300#s1763 | In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. | 0001213900-25-026300 | Agrify 8-K 2025-03-31 | 6 | 1,763 | 1,537 |
0001213900-25-026300#s2082 | The forward-looking statements in this Current Report on Form 8-K are only predictions. | 0001213900-25-026300 | Agrify 8-K 2025-03-31 | 7 | 2,082 | 2,169 |
0001213900-25-026300#s2170 | The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its business, financial condition and results of operations. | 0001213900-25-026300 | Agrify 8-K 2025-03-31 | 8 | 2,170 | 2,318 |
0001213900-25-026300#s2718 | Investors should carefully consider the risks and uncertainties that affect the Company’s business, including those described in our filings with the Securities and Exchange Commission (“SEC”), including under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K filed for the year ended December 31, 2... | 0001213900-25-026300 | Agrify 8-K 2025-03-31 | 9 | 2,718 | 2,476 |
0001213900-25-026300#s3113 | These forward-looking statements speak only as of the date of this communication. | 0001213900-25-026300 | Agrify 8-K 2025-03-31 | 10 | 3,113 | 2,163 |
0001213900-25-026300#s3195 | Except as required by applicable law, the Company does not plan to publicly update or revise any forward-looking statements, whether as a result of any new information, future events or otherwise. | 0001213900-25-026300 | Agrify 8-K 2025-03-31 | 11 | 3,195 | 2,278 |
0001213900-25-026300#s3392 | Investors are advised, however, to consult any further disclosures the Company makes on related subjects in our public announcements and filings with the SEC. | 0001213900-25-026300 | Agrify 8-K 2025-03-31 | 12 | 3,392 | 2,240 |
0001193125-23-079181#s428 | The Company plans to reduce its workforce by approximately 28%, decreasing its headcount by approximately 23 employees, predominantly from the Company’s detection business unit. | 0001193125-23-079181 | Icad 8-K 2023-03-24 | 0 | 428 | 188 |
0001193125-23-079181#s606 | Xoft, Inc., a wholly-owned subsidiary of the Company, will also furlough 12 of its employees, or approximately 50% of its workforce. | 0001193125-23-079181 | Icad 8-K 2023-03-24 | 1 | 606 | 143 |
0001193125-23-079181#s739 | The Company currently estimates it will incur one-time cash pre-tax restructuring charges of an aggregate of approximately $0.3 million in the first half of 2023 as a result of the RIF, comprised primarily of one-time severance and benefits payments, and employee-related transition costs. | 0001193125-23-079181 | Icad 8-K 2023-03-24 | 2 | 739 | 300 |
0001193125-23-079181#s1029 | Estimated amounts are subject to change until finalized and the Company may incur additional costs during the remainder of 2023. | 0001193125-23-079181 | Icad 8-K 2023-03-24 | 3 | 1,029 | 139 |
0001193125-23-079181#s1187 | This Current Report on Form 8-K contains statements that relate to future events and expectations, including those relating to the RIF and the Company’s expectations regarding the timing of the RIF and types and estimates of associated costs and financial impact, and as such constitute forward-looking statements within... | 0001193125-23-079181 | Icad 8-K 2023-03-24 | 4 | 1,187 | 1,576 |
0001193125-23-079181#s1940 | All statements by the Company that reflect expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements. | 0001193125-23-079181 | Icad 8-K 2023-03-24 | 5 | 1,940 | 1,362 |
0001193125-23-079181#s2303 | Although the Company believes that the expectations reflected in any forward-looking statements are based on reasonable assumptions, it can give no assurance that these expectations will be attained, and it is possible that actual results may differ materially from those indicated by these forward-looking statements du... | 0001193125-23-079181 | Icad 8-K 2023-03-24 | 6 | 2,303 | 1,549 |
0001193125-23-079181#s2666 | The Company disclaims any obligation to update publicly any forward-looking statements, whether in response to new information, future events or otherwise, except as required by applicable law. | 0001193125-23-079181 | Icad 8-K 2023-03-24 | 7 | 2,666 | 1,380 |
0001193125-23-079181#s2860 | Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. | 0001193125-23-079181 | Icad 8-K 2023-03-24 | 8 | 2,860 | 1,329 |
0001193125-23-079181#s3003 | For additional disclosure regarding these and other risks faced by the Company, please see the disclosure contained in our public filings with the Securities and Exchange Commission (the “SEC”), available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov. | 0001193125-23-079181 | Icad 8-K 2023-03-24 | 9 | 3,003 | 1,505 |
0001193125-23-079181#s3417 | 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). | 0001193125-23-079181 | Icad 8-K 2023-03-24 | 10 | 3,417 | 3,497 |
0001193125-25-223434#s62 | On September 29, 2025, Sutro Biopharma, Inc. (the “Company”) announced further organizational restructuring to prioritize the advancement of its three preclinical ADC programs and its research and development collaborations. | 0001193125-25-223434 | Sutro Biopharma 8-K 2025-09-29 | 0 | 62 | 286 |
0001193125-25-223434#s287 | The restructuring is expected to extend the Company’s runway into at least mid-2027 resulting from cost savings associated with the restructuring and certain expected near-term milestone payments. | 0001193125-25-223434 | Sutro Biopharma 8-K 2025-09-29 | 1 | 287 | 258 |
0001193125-25-223434#s484 | Following further prioritization of the ADC programs, the Company expects initial clinical data to be available from STRO-004, its next-generation Tissue Factor-targeting exatecan ADC, in 2026. | 0001193125-25-223434 | Sutro Biopharma 8-K 2025-09-29 | 2 | 484 | 255 |
0001193125-25-223434#s678 | As part of the corporate restructuring, the Company plans to reduce its workforce by approximately one-third. | 0001193125-25-223434 | Sutro Biopharma 8-K 2025-09-29 | 3 | 678 | 171 |
0001193125-25-223434#s788 | The total cash payments and costs related to the further prioritization of the ADC programs and reducing the workforce are estimated to be approximately $4.1million to $4.3 million, with a significant majority of these amounts expected to be paid in the fourth quarter of 2025. | 0001193125-25-223434 | Sutro Biopharma 8-K 2025-09-29 | 4 | 788 | 1,065 |
0001193125-25-223434#s1066 | These estimates are subject to a number of assumptions and actual results may differ. | 0001193125-25-223434 | Sutro Biopharma 8-K 2025-09-29 | 5 | 1,066 | 873 |
0001193125-25-223434#s1152 | The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the corporate restructuring. | 0001193125-25-223434 | Sutro Biopharma 8-K 2025-09-29 | 6 | 1,152 | 961 |
0001193125-25-223434#s1326 | A copy of the press release announcing the corporate restructuring is attached as Exhibit 99.1 to this Current Report on Form 8-K. | 0001193125-25-223434 | Sutro Biopharma 8-K 2025-09-29 | 7 | 1,326 | 1,456 |
0001193125-25-223434#s1535 | Description 99.1 Press Release issued by Sutro Biopharma, Inc. announcing operational restructuring intended to extend cash runway through key milestones. | 0001193125-25-223434 | Sutro Biopharma 8-K 2025-09-29 | 8 | 1,535 | 1,689 |
0001193125-25-223434#s1690 | 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) | 0001193125-25-223434 | Sutro Biopharma 8-K 2025-09-29 | 9 | 1,690 | 1,769 |
0001193125-25-223434#s1799 | This Current Report on Form 8-K contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, and other federal securities laws. | 0001193125-25-223434 | Sutro Biopharma 8-K 2025-09-29 | 10 | 1,799 | 2,009 |
0001193125-25-223434#s2010 | Any statements contained herein that do not describe historical facts, including, but not limited to, statements regarding anticipated preclinical and clinical development activities; timing of announcements of IND submissions, clinical results, trial initiation, and other regulatory filings; outcome of discussions wit... | 0001193125-25-223434 | Sutro Biopharma 8-K 2025-09-29 | 11 | 2,010 | 2,699 |
0001193125-25-223434#s2911 | Such risks and uncertainties include, among others, the risks identified in the Company’s filings with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 13, 2025. | 0001193125-25-223434 | Sutro Biopharma 8-K 2025-09-29 | 12 | 2,911 | 2,034 |
0001193125-25-223434#s3147 | Any of these risks and uncertainties could materially and adversely affect the Company’s results of operations, which would, in turn, have a significant and adverse impact on the Company’s stock price. | 0001193125-25-223434 | Sutro Biopharma 8-K 2025-09-29 | 13 | 3,147 | 2,000 |
0001193125-25-223434#s3349 | The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. | 0001193125-25-223434 | Sutro Biopharma 8-K 2025-09-29 | 14 | 3,349 | 1,933 |
0001193125-25-223434#s3484 | The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events. | 0001193125-25-223434 | Sutro Biopharma 8-K 2025-09-29 | 15 | 3,484 | 2,021 |
0000713676-23-000069#s57 | On , The PNC Financial Services Group, Inc. (the “Corporation”) issued a press release regarding the Corporation’s earnings and business results for the third quarter of 2023. | 0000713676-23-000069 | PNC Financial Services Group 8-K 2023-10-13 | 0 | 57 | 232 |
0000713676-23-000069#s233 | A copy of the Corporation’s press release is included in this Report as Exhibit 99.1 and is furnished herewith. | 0000713676-23-000069 | PNC Financial Services Group 8-K 2023-10-13 | 1 | 233 | 168 |
0000713676-23-000069#s345 | In connection therewith, the Corporation provided supplementary financial information on its website. | 0000713676-23-000069 | PNC Financial Services Group 8-K 2023-10-13 | 2 | 345 | 446 |
0000713676-23-000069#s447 | A copy of the Corporation’s supplementary financial information is included in this Report as Exhibit 99.2 and is furnished herewith. | 0000713676-23-000069 | PNC Financial Services Group 8-K 2023-10-13 | 3 | 447 | 478 |
0000713676-23-000069#s642 | On October 6, 2023, as part of ongoing cost reduction initiatives, the Corporation committed to a workforce reduction expected to reduce its workforce by approximately 4 percent. | 0000713676-23-000069 | PNC Financial Services Group 8-K 2023-10-13 | 4 | 642 | 820 |
0000713676-23-000069#s821 | Affected employees were informed of the workforce reduction beginning on October 6, 2023. | 0000713676-23-000069 | PNC Financial Services Group 8-K 2023-10-13 | 5 | 821 | 731 |
0000713676-23-000069#s911 | The Corporation expects to incur one-time, pre-tax charges and costs associated with these actions of approximately $150 million, primarily related to cash severance, benefits and related termination costs. | 0000713676-23-000069 | PNC Financial Services Group 8-K 2023-10-13 | 6 | 911 | 848 |
0000713676-23-000069#s1118 | The Corporation expects that the majority of the charges will be incurred in the fourth quarter of 2023. | 0000713676-23-000069 | PNC Financial Services Group 8-K 2023-10-13 | 7 | 1,118 | 746 |
0000713676-23-000069#s1223 | The Corporation anticipates that implementation of the workforce reduction will be almost entirely complete in the fourth quarter of 2023, and will reduce personnel expenses by approximately $325 million, or 5 percent, annually (estimated based on the annualized pre-reduction personnel expense of affected employees, co... | 0000713676-23-000069 | PNC Financial Services Group 8-K 2023-10-13 | 8 | 1,223 | 997 |
0000713676-23-000069#s1640 | This Report contains forward-looking statements regarding the Corporation’s anticipated size and timing of a workforce reduction, and the associated costs and cash expenditures and savings. | 0000713676-23-000069 | PNC Financial Services Group 8-K 2023-10-13 | 9 | 1,640 | 1,829 |
0000713676-23-000069#s1955 | Future events or circumstances may change our outlook and may also affect the nature of the assumptions, risks and uncertainties to which our forward-looking statements are subject. | 0000713676-23-000069 | PNC Financial Services Group 8-K 2023-10-13 | 10 | 1,955 | 1,821 |
0000713676-23-000069#s2137 | The forward-looking statements in this Report speak only as of the date of this Report, and we assume no duty, and do not undertake, to update them. | 0000713676-23-000069 | PNC Financial Services Group 8-K 2023-10-13 | 11 | 2,137 | 1,788 |
0000713676-23-000069#s2286 | Actual results or future events could differ, possibly materially, from those that we anticipated in these forward-looking statements. | 0000713676-23-000069 | PNC Financial Services Group 8-K 2023-10-13 | 12 | 2,286 | 1,774 |
0000713676-23-000069#s2421 | As a result, we caution against placing undue reliance on any forward-looking statements. | 0000713676-23-000069 | PNC Financial Services Group 8-K 2023-10-13 | 13 | 2,421 | 1,729 |
0000713676-23-000069#s2954 | These forward-looking statements are also subject to the principal risks and uncertainties applicable to our businesses generally that are disclosed in our 2022 Form 10-K and in our subsequent filings with the Securities and Exchange Commission. | 0000713676-23-000069 | PNC Financial Services Group 8-K 2023-10-13 | 14 | 2,954 | 1,885 |
0000713676-23-000069#s3259 | Number Description Method of Filing 99.1 Press release dated October 13, 2023 Furnished herewith 99.2 Financial Supplement (unaudited) for the Third Quarter 2023 Furnished herewith 104 The cover page of this Current Report on Form 8-K, formatted in Inline XBRL. | 0000713676-23-000069 | PNC Financial Services Group 8-K 2023-10-13 | 15 | 3,259 | 3,506 |
0001999371-24-006472#s62 | Tonix Pharmaceuticals Holding Corp. (the “Company”) plans to reduce its workforce by 23 full-time employees and decommission its Advanced Development Center (“ADC”) in Massachusetts by June 7, 2024, to align the Company’s capital and human resources with its previously announced strategic prioritization of its Tonmya™ ... | 0001999371-24-006472 | Tonix Pharmaceuticals Holding 8-K 2024-05-22 | 0 | 62 | 487 |
0001999371-24-006472#s488 | At this time the Company has made a good faith determination that it does not expect to incur a material charge in connection with the reduction in force or decommissioning of the ADC. | 0001999371-24-006472 | Tonix Pharmaceuticals Holding 8-K 2024-05-22 | 1 | 488 | 672 |
0001999371-24-006472#s706 | The information in Item 2.05 above is incorporated herein by reference. | 0001999371-24-006472 | Tonix Pharmaceuticals Holding 8-K 2024-05-22 | 2 | 706 | 755 |
0001999371-24-006472#s778 | At this time the Company is unable to make a good faith determination of the amount or range of the non-cash impairment charge or the impairment charge that will result in future cash expenditures related to the decommissioning of the ADC. | 0001999371-24-006472 | Tonix Pharmaceuticals Holding 8-K 2024-05-22 | 3 | 778 | 923 |
0001999371-24-006472#s1029 | Submission of Matters to a Vote of Security Holders. | 0001999371-24-006472 | Tonix Pharmaceuticals Holding 8-K 2024-05-22 | 4 | 1,029 | 1,081 |
0001999371-24-006472#s1082 | On May 22, 2024, the Company held its annual meeting of shareholders, at which the Company’s shareholders approved four proposals. | 0001999371-24-006472 | Tonix Pharmaceuticals Holding 8-K 2024-05-22 | 5 | 1,082 | 1,212 |
0001999371-24-006472#s1213 | Shareholders representing 43,505,606 shares, or 61.6%, of the common shares outstanding as of the March 25, 2024 record date, were represented at the meeting by proxy. | 0001999371-24-006472 | Tonix Pharmaceuticals Holding 8-K 2024-05-22 | 6 | 1,213 | 1,249 |
0001999371-24-006472#s1381 | The proposals are described in detail in the Company’s proxy statement filed with the Securities and Exchange Commission on April 15, 2024, pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended. | 0001999371-24-006472 | Tonix Pharmaceuticals Holding 8-K 2024-05-22 | 7 | 1,381 | 1,299 |
0001193125-25-245102#s57 | On October 21, 2025, the Company issued a press release announcing data results from the Company’s Phase 3 INFRONT-3 clinical trial that included its preliminary estimate of cash, cash equivalents, and short-term investments as of September 30, 2025. | 0001193125-25-245102 | Alector 8-K 2025-10-21 | 0 | 57 | 307 |
0001193125-25-245102#s308 | A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference. | 0001193125-25-245102 | Alector 8-K 2025-10-21 | 1 | 308 | 150 |
0001193125-25-245102#s402 | The information contained under Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed inco... | 0001193125-25-245102 | Alector 8-K 2025-10-21 | 2 | 402 | 921 |
0001193125-25-245102#s983 | On October 21, 2025, the Company committed to a plan to reduce its workforce (the “Plan”) by approximately 49% in order to align resources with the Company’s strategic priorities. | 0001193125-25-245102 | Alector 8-K 2025-10-21 | 3 | 983 | 1,162 |
0001193125-25-245102#s1163 | Based upon the results of the Company’s Phase 3 INFRONT-3 clinical trial evaluating the safety and efficacy of latozinemab (AL001) in individuals with frontotemporal dementia due to a GRN mutation (FTD- GRN ), the Company is discontinuing the open-label extension portion of the INFRONT-3 trial and the continuation stud... | 0001193125-25-245102 | Alector 8-K 2025-10-21 | 4 | 1,163 | 1,321 |
0001193125-25-245102#s1502 | The Company initiated a reduction in force impacting approximately 75 employees across the organization. | 0001193125-25-245102 | Alector 8-K 2025-10-21 | 5 | 1,502 | 1,087 |
0001193125-25-245102#s1607 | Total incremental restructuring charges associated with the reduction in force are expected to be approximately $7.7 million. | 0001193125-25-245102 | Alector 8-K 2025-10-21 | 6 | 1,607 | 1,732 |
0001193125-25-245102#s1733 | The Plan includes severance and related termination benefits for affected employees. | 0001193125-25-245102 | Alector 8-K 2025-10-21 | 7 | 1,733 | 1,691 |
0001193125-25-245102#s1818 | Cash payments related to these expenses will be paid out and the reduction in force is expected to be completed during the first half of 2026. | 0001193125-25-245102 | Alector 8-K 2025-10-21 | 8 | 1,818 | 1,749 |
0001193125-25-245102#s1961 | The estimated costs that the Company expects to incur in connection with the reduction are subject to a number of assumptions, and actual results may differ significantly from these estimates. | 0001193125-25-245102 | Alector 8-K 2025-10-21 | 9 | 1,961 | 1,799 |
0001193125-25-245102#s2154 | The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the reduction. | 0001193125-25-245102 | Alector 8-K 2025-10-21 | 10 | 2,154 | 1,766 |
0001193125-25-245102#s2471 | On October 20, 2025, Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development of the Company, informed the Company of her resignation from her position effective December 22, 2025, to pursue other professional opportunities. | 0001193125-25-245102 | Alector 8-K 2025-10-21 | 11 | 2,471 | 2,712 |
0001193125-25-245102#s2713 | Dr. Kenkare-Mitra’s resignation is not the result of any disagreement with the Company related to its operations, policies, or practices. | 0001193125-25-245102 | Alector 8-K 2025-10-21 | 12 | 2,713 | 2,608 |
0001193125-25-245102#s2851 | The Company thanks Dr. Kenkare-Mitra for her dedication over her years of service to the Company. | 0001193125-25-245102 | Alector 8-K 2025-10-21 | 13 | 2,851 | 2,568 |
0001193125-25-245102#s2949 | In connection with Dr. Kenkare-Mitra’s resignation, Dr. Kenkare-Mitra and the Company have agreed to enter into a separation agreement. | 0001193125-25-245102 | Alector 8-K 2025-10-21 | 14 | 2,949 | 3,084 |
0001193125-25-245102#s3085 | Under the separation agreement, Dr. Kenkare-Mitra will be paid a lump-sum cash payment equal to nine months of her annual base salary and a payment equal to 50% of her annual bonus target, and she will receive nine months of Company-paid premiums for COBRA coverage. | 0001193125-25-245102 | Alector 8-K 2025-10-21 | 15 | 3,085 | 3,215 |
0001193125-25-245102#s3352 | In consideration for such compensation, Dr. Kenkare-Mitra will agree to a customary general release of claims for the benefit of the Company. | 0001193125-25-245102 | Alector 8-K 2025-10-21 | 16 | 3,352 | 3,090 |
0001193125-25-245102#s3494 | The foregoing description of the separation agreement does not purport to be complete and is qualified by reference to the separation agreement, which the Company intends to file with the Securities and Exchange Commission as an exhibit to a subsequent periodic report. | 0001193125-25-245102 | Alector 8-K 2025-10-21 | 17 | 3,494 | 3,218 |
0001193125-25-245102#s3800 | On October 21, 2025, the Company issued a press release announcing data results from the Company’s Phase 3 INFRONT-3 clinical trial evaluating the Company’s latozinemab (AL001) product candidate and the Plan described above. | 0001193125-25-245102 | Alector 8-K 2025-10-21 | 18 | 3,800 | 4,024 |
0001193125-25-245102#s4025 | A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference. | 0001193125-25-245102 | Alector 8-K 2025-10-21 | 19 | 4,025 | 3,893 |
0001193125-25-245102#s4119 | The information contained under Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities A... | 0001193125-25-245102 | Alector 8-K 2025-10-21 | 20 | 4,119 | 4,536 |
0001193125-25-245102#s4537 | Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements as that term is defined in Section 27A of the Securities Act and Section 21E of the Exchange Act. | 0001193125-25-245102 | Alector 8-K 2025-10-21 | 21 | 4,537 | 4,744 |
0001193125-25-245102#s4745 | Such forward-looking statements involve substantial risks and uncertainties. | 0001193125-25-245102 | Alector 8-K 2025-10-21 | 22 | 4,745 | 4,613 |
0001193125-25-245102#s4822 | All statements other than statements of historical fact contained in this Form 8-K are forward-looking statements, including statements relating to the Company’s plans, expectations, forecasts and future events. | 0001193125-25-245102 | Alector 8-K 2025-10-21 | 23 | 4,822 | 4,748 |
0001193125-25-245102#s5034 | Such forward-looking statements include, but are not limited to, statements relating to the potential of, and expectations regarding, the Company’s business strategy, and statements relating to the anticipated timing and details of the Plan and the expected impacts, charges and costs associated with the Plan that the C... | 0001193125-25-245102 | Alector 8-K 2025-10-21 | 24 | 5,034 | 4,881 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.